基线结肠镜检查发现3-4个非进展期腺瘤患者异时性结直肠进展期肿瘤和癌症风险:系统综述与Meta分析
该系统综述与Meta分析纳入15项研究共36375例患者,比较基线结肠镜发现1-2个、3-4个及≥5个非进展期腺瘤者异时性进展期肿瘤和结直肠癌风险。3-4个组异时性进展期肿瘤风险显著高于1-2个组(RR 1.264),但与≥5个组无差异;异时性结直肠癌风险各组间均无显著差异。作者认为需进一步研究以确认3-4个组是否可采用≥5年间隔的监测结肠镜。
要点
- 3-4个非进展期腺瘤组异时性进展期肿瘤风险显著高于1-2个组(RR 1.264,95%CI 1.053-1.518)。
- 3-4个组与≥5个组异时性进展期肿瘤风险无显著差异(RR 1.962,95%CI 0.972-3.958)。
- 异时性结直肠癌风险在1-2个与3-4个组间及3-4个与≥5个组间均无显著差异。
核心结论
- 3-4个非进展期腺瘤组异时性进展期肿瘤风险高于1-2个组,但3-4个组与≥5个组异时性进展期肿瘤和结直肠癌风险无差异。
- 作者认为需进一步研究3-4个非进展期腺瘤组的异时性进展期肿瘤和结直肠癌风险,以确认是否可采用≥5年间隔的监测结肠镜。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE、EMBASE和Cochrane Library数据库至2021年1月。
- 纳入15项研究,共36375例患者,比较基线结肠镜发现1-2个、3-4个和≥5个非进展期腺瘤三组的异时性进展期肿瘤和结直肠癌风险。
- 采用随机效应模型评估异时性进展期肿瘤和结直肠癌风险。
主要发现
- 3-4个非进展期腺瘤组异时性进展期肿瘤风险显著高于1-2个组(RR 1.264,95%CI 1.053-1.518,P=0.012;I²=0%)。
- ≥5个非进展期腺瘤组与3-4个组异时性进展期肿瘤风险无显著差异(RR 1.962,95%CI 0.972-3.958,P=0.060;I²=68%)。
- 1-2个与3-4个非进展期腺瘤组异时性结直肠癌风险无显著差异(RR 2.663,95%CI 0.391-18.128,P=0.317;I²=0%)。
- 3-4个与≥5个非进展期腺瘤组异时性结直肠癌风险无显著差异(RR 1.148,95%CI 0.142-9.290,P=0.897;I²=0%)。
关键数值与推荐
- 3-4个非进展期腺瘤组 vs 1-2个组:异时性进展期肿瘤风险RR 1.264(95%CI 1.053-1.518,P=0.012;I²=0%)。
- ≥5个非进展期腺瘤组 vs 3-4个组:异时性进展期肿瘤风险RR 1.962(95%CI 0.972-3.958,P=0.060;I²=68%)。
- 1-2个 vs 3-4个非进展期腺瘤组:异时性结直肠癌风险RR 2.663(95%CI 0.391-18.128,P=0.317;I²=0%)。
- 3-4个 vs ≥5个非进展期腺瘤组:异时性结直肠癌风险RR 1.148(95%CI 0.142-9.290,P=0.897;I²=0%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- ≥5个与3-4个非进展期腺瘤组异时性进展期肿瘤风险比较的异质性I²=68%。
- 作者认为需进一步研究3-4个非进展期腺瘤组的异时性进展期肿瘤和结直肠癌风险,以确认是否可采用≥5年间隔的监测结肠镜。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: This systematic review and meta-analysis evaluated the available evidence on the risk of metachronous advanced neoplasia (AN) and colorectal cancer (CRC) in patients with 3-4 nonadvanced adenomas (NAAs). METHODS: We searched MEDLINE, EMBASE, and Cochrane Library databases up to January 2021 for studies evaluating metachronous AN and CRC risk by comparing 3 groups (1-2 vs 3-4 vs ≥5 NAAs) at index colonoscopy. The estimates for risk of metachronous AN and CRC were evaluated using random-effects models. RESULTS: Fifteen studies (n = 36,375) were included. The risk of metachronous AN was significantly higher in the 3-4 NAAs group than in the 1-2 NAAs group (relative risk [RR] 1.264, 95% confidence interval [CI] 1.053-1.518, P = 0.012; I2 = 0%); there was no difference between the ≥ 5 NAAs and 3-4 NAAs groups (RR 1.962, 95% CI 0.972-3.958, P = 0.060; I2 = 68%). The risks of metachronous CRC between the 1-2 NAAs and 3-4 NAAs groups (RR 2.663, 95% CI 0.391-18.128, P = 0.317; I2 = 0%) or the 3-4 NAAs and ≥ 5 NAAs groups (RR 1.148, 95% CI 0.142-9.290, P = 0.897; I2 = 0%) were not significantly different. DISCUSSION: Although the risk of metachronous AN was greater in the 3-4 NAAs group than in the 1-2 NAAs group, the risk of metachronous AN and CRC between the 3-4 NAAs and ≥ 5 NAAs groups was not different. This suggests that further studies on metachronous AN and CRC risk in the 3-4 NAAs group are warranted to confirm a firm ≥5-year interval surveillance colonoscopy.
引用
- Park S, Jeon SR, Kim HG, et al. Risk of Metachronous Colorectal Advanced Neoplasia and Cancer in Patients With 3-4 Nonadvanced Adenomas at Index Colonoscopy: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2022. PMID: 35169108. doi:10.14309/ajg.0000000000001682
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。